Keywords: Lung cancer, Individualized chemotherapy, NSCLC, In vitro HDRA

Lung cancer survival rates improved through use of individualized chemotherapy

Article | 03 September 2010

Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in